ParkinsonCanadaV1, Main, Exploration, bibRecord, 002048

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly

Identifieur interne : 002048 ( Main/Exploration ); précédent : 002047; suivant : 002049

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly

Auteurs : Peter J. Trainer [Royaume-Uni] ; Shereen Ezzat [Canada] ; Gwyn A. D Ouza [Royaume-Uni] ; Gary Layton [Royaume-Uni] ; Christian J. Strasburger [Allemagne]

Source :

Clinical Endocrinology [ 0300-0664 ] ; 2009-10.

RBID : ISTEX:118422474E51D80C9AA8133AFE629BCABE07B9B6

Abstract

Objective For patients with acromegaly who are suboptimally controlled on long‐acting octreotide (LAR), treatment options are to switch to pegvisomant monotherapy (PM) or add pegvisomant to LAR (P‐LAR). Our objective was to evaluate if the safety and efficacy of these regimens differ.

Url:

https://api-v5.istex.fr/document/118422474E51D80C9AA8133AFE629BCABE07B9B6/fulltext/pdf

DOI: 10.1111/j.1365-2265.2009.03620.x

Affiliations:

Allemagne, Canada, Royaume-Uni
Angleterre, Berlin, Grand Manchester, Ontario
Berlin, Manchester, Toronto
Université de Toronto

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 001932
to stream Istex, to step Curation: 001932
to stream Istex, to step Checkpoint: 000824
to stream Main, to step Merge: 002201
to stream Main, to step Curation: 002048

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly</title>
<author><name sortKey="Trainer, Peter J" sort="Trainer, Peter J" uniqKey="Trainer P" first="Peter J." last="Trainer">Peter J. Trainer</name>
</author>
<author><name sortKey="Ezzat, Shereen" sort="Ezzat, Shereen" uniqKey="Ezzat S" first="Shereen" last="Ezzat">Shereen Ezzat</name>
</author>
<author><name sortKey="D Ouza, Gwyn A" sort="D Ouza, Gwyn A" uniqKey="D Ouza G" first="Gwyn A." last="D Ouza">Gwyn A. D Ouza</name>
</author>
<author><name sortKey="Layton, Gary" sort="Layton, Gary" uniqKey="Layton G" first="Gary" last="Layton">Gary Layton</name>
</author>
<author><name sortKey="Strasburger, Christian J" sort="Strasburger, Christian J" uniqKey="Strasburger C" first="Christian J." last="Strasburger">Christian J. Strasburger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:118422474E51D80C9AA8133AFE629BCABE07B9B6</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1111/j.1365-2265.2009.03620.x</idno>
<idno type="url">https://api-v5.istex.fr/document/118422474E51D80C9AA8133AFE629BCABE07B9B6/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001932</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001932</idno>
<idno type="wicri:Area/Istex/Curation">001932</idno>
<idno type="wicri:Area/Istex/Checkpoint">000824</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000824</idno>
<idno type="wicri:doubleKey">0300-0664:2009:Trainer P:a:randomized:controlled</idno>
<idno type="wicri:Area/Main/Merge">002201</idno>
<idno type="wicri:Area/Main/Curation">002048</idno>
<idno type="wicri:Area/Main/Exploration">002048</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly</title>
<author><name sortKey="Trainer, Peter J" sort="Trainer, Peter J" uniqKey="Trainer P" first="Peter J." last="Trainer">Peter J. Trainer</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Endocrinology, Christie Hospital, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ezzat, Shereen" sort="Ezzat, Shereen" uniqKey="Ezzat S" first="Shereen" last="Ezzat">Shereen Ezzat</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto, ON</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="D Ouza, Gwyn A" sort="D Ouza, Gwyn A" uniqKey="D Ouza G" first="Gwyn A." last="D Ouza">Gwyn A. D Ouza</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Sandwich Laboratories, Pfizer Global Research and Development, Sandwich, Kent</wicri:regionArea>
<wicri:noRegion>Kent</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Layton, Gary" sort="Layton, Gary" uniqKey="Layton G" first="Gary" last="Layton">Gary Layton</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Sandwich Laboratories, Pfizer Global Research and Development, Sandwich, Kent</wicri:regionArea>
<wicri:noRegion>Kent</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Strasburger, Christian J" sort="Strasburger, Christian J" uniqKey="Strasburger C" first="Christian J." last="Strasburger">Christian J. Strasburger</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Endocrinology, Charité University Medicine, Charité Campus Mitte, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Clinical Endocrinology</title>
<idno type="ISSN">0300-0664</idno>
<idno type="eISSN">1365-2265</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2009-10">2009-10</date>
<biblScope unit="volume">71</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="549">549</biblScope>
<biblScope unit="page" to="557">557</biblScope>
</imprint>
<idno type="ISSN">0300-0664</idno>
</series>
<idno type="istex">118422474E51D80C9AA8133AFE629BCABE07B9B6</idno>
<idno type="DOI">10.1111/j.1365-2265.2009.03620.x</idno>
<idno type="ArticleID">CEN3620</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0300-0664</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Objective  For patients with acromegaly who are suboptimally controlled on long‐acting octreotide (LAR), treatment options are to switch to pegvisomant monotherapy (PM) or add pegvisomant to LAR (P‐LAR). Our objective was to evaluate if the safety and efficacy of these regimens differ.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Canada</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Berlin</li>
<li>Grand Manchester</li>
<li>Ontario</li>
</region>
<settlement><li>Berlin</li>
<li>Manchester</li>
<li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Trainer, Peter J" sort="Trainer, Peter J" uniqKey="Trainer P" first="Peter J." last="Trainer">Peter J. Trainer</name>
</region>
<name sortKey="D Ouza, Gwyn A" sort="D Ouza, Gwyn A" uniqKey="D Ouza G" first="Gwyn A." last="D Ouza">Gwyn A. D Ouza</name>
<name sortKey="Layton, Gary" sort="Layton, Gary" uniqKey="Layton G" first="Gary" last="Layton">Gary Layton</name>
</country>
<country name="Canada"><region name="Ontario"><name sortKey="Ezzat, Shereen" sort="Ezzat, Shereen" uniqKey="Ezzat S" first="Shereen" last="Ezzat">Shereen Ezzat</name>
</region>
</country>
<country name="Allemagne"><region name="Berlin"><name sortKey="Strasburger, Christian J" sort="Strasburger, Christian J" uniqKey="Strasburger C" first="Christian J." last="Strasburger">Christian J. Strasburger</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002048 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002048 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:118422474E51D80C9AA8133AFE629BCABE07B9B6
   |texte=   A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri